Rheumatoid arthritis (RA) is characterized by an autoimmunological inflammation. Synovitis of affected joints generates a destructively growing tissue that causes degradative and erosive lesions of cartilage and juxtaarticular bones w1x. In contrast, osteoarthritis (OA) is characterized by degenerative loss of cartilage, bone remodelling and an intermittent synovitis without the destructive potency seen in RA w2, 3x. Different diagnostic methods such as conventional radiography, tomography procedures, sonography and arthroscopy have been developed to document the state of destruction in both RA and OA, but it remains difficult to describe the dynamics of degradation depending on the current inflammatory activity.
It is commonly accepted that the occurrence of the collagen hydroxypyridinium crosslinks pyridinoline and deoxypyridinoline in urine is an indication of the breakdown of mature collagen w4x. Deoxypyridinoline is released mainly from bone and dentin and, because of its low turnover, in insignificant amounts from collagen of tendons and aorta, whereas pyridinoline is the major crosslink of cartilage and is also prevalent in the collagen of bone and other tissues w5x.
There are some reports which suggest that increased excretion of pyridinium crosslinks correlates positively with disease activity in RA patients w6, 7x. But analysis of these crosslinks in joint tissues is rare and only performed on a small number of patients w8, 9x. As data from studies showing the level of synovial tissue collagen crosslinking in the presence of active RA are lacking, the origins of elevated concentrations of urinary crosslinks remains unclear. Other pathological processes associated with RA, such as osteoporosis, infection of internal organs, coexisting osteoarthritis or treatment with corticosteroids may contribute to increased crosslink excretion w10, 11x.
In this study, we investigated pyridinoline and deoxypyridinoline simultaneously in synovial tissue, synovial fluid, serum and urine in patients with RA and OA, to examine the effect of inflammation on the crosslinking of synovial tissue mature collagen and to specify the significance of the urinary excreted pyridinium crosslinks as markers of collagen degradation in the presence of disease activity in RA.
Patients and methods

Subjects and samples
Twenty-two patients suffering from RA, diagnosed according to the 1987 revised criteria of the American Rheumatism Association (ARA), and 21 patients with osteoarthritis were studied. According to their C-reactive protein (CRP), RA patients were divided into two groups: 12 patients with inactive RA or low disease activity of the RA (iRA: CRP <28 mgul) and 10 patients with active RA (aRA: CRP 028 mgul). The characteristics of patients are summarized in Table 1 . Articular prechondral synovial tissue and synovial fluid was obtained from total knee replacement surgery and thereafter immediately frozen in liquid nitrogen and stored at 2808C. Serum and urine were collected in the morning before breakfast (before surgery and perioperative steroid boli) and were centrifuged at 3000 g for 5 min at 48C and stored at 2808C before being assayed. Collection procedures were in accordance with the principles of the 1975 Declaration of Helsinki, as revised in 1983.
Analytical techniques
Standard laboratory methods were used including nephelometry for CRP, Westergren method for erythrocyte sedimentation rate (ESR) and Jaffe rate technique in duplicate for urinary creatinine.
The synovial tissue was fragmented, freeze-dried under vacuum, weighed and approximately 20 mg were restored with 3:1 trichloromethane:methanol for exhaustive extraction. One aliquot of the synovial tissue collagen sample as well as samples of synovial fluid, serum and urine were prepared for HPLC measurement of pyridinoline and deoxypyridinoline as described w7, 12x, including pretreatment of samples by hydrolysis (32% hydrochloric acid, 17 h, 1108C) and fractionation of hydrolysates by manual partition chromatography on CF1 cellulose to remove interfering fluorescent components w13x. Investigation of pyridinoline and deoxypyridinoline was performed using ion-paired reversed-phase HPLC and gradient separation under fluorescence detection w14x, modified according to Mueller et al. w7x . For quantification, the HPLC method was calibrated with a purified standard containing defined amounts of pyridinoline and deoxypyridinoline. The cycle time for one determination was 30 min. The limits of detection of the assay were 25 fmol for pyridinoline and 56 fmol for deoxypyridinoline.
Another synovial tissue collagen sample aliquot was taken for HPLC measurement of hydroxyproline w15x. Assuming that 300 hydroxyproline residues represent one collagen molecule Collagen crosslinking density of RA synovium 315 Collagen crosslinking density of RA synovium 315 w8x, pyridinium crosslinks in synovial tissue were specified as molumol collagen. Pyridinoline and deoxypyridinoline levels in synovial fluid and serum were expressed as nmolul, and urinary crosslinks after creatinine correction as nmolumol creatinine.
Statistical analysis
Analysis of variance was performed using the Kruskal-Wallis test. For comparison of non-parametric variables between the patient groups the Mann-Whitney U-test was used. Correlation coefficients were analysed according to Spearman. P values (0.05 were considered to be significant. All calculations were performed using the statistical software package SPSS version 10.0.
Results
Patient characteristics, including age, duration of disease, sex distribution and acute-phase reactant levels are shown in Table 1 , together with comparison of means of these parameters within the diagnosis groups. The means for pyridinoline, deoxypyridinoline and calculated pyridinolineudeoxypyridinoline (PyruDpyr) ratio in synovial tissue, synovial fluid, serum and urine within the diagnosis groups aRA, iRA and OA are displayed in Table 2 . Total pyridinoline concentrations in synovial tissue were found to be significantly elevated in patients with aRA compared with those with iRA (P<0.005) and OA (P<0.05). No difference in pyridinoline levels was seen between iRA and OA patients and in deoxypyridinoline levels between all groups. Subsequently the PyruDpyr ratio was shown to be significantly increased in all RA patients (21.8"7.7) compared with OA (P<0.001) and in the aRA group compared with iRA (P<0.05) and OA (P<0.0005) (Fig. 1) . The PyruDpyr ratio in synovial tissue of RA patients was correlated with the acutephase reactants ESR (r=0.571, P<0.05) and CRP (r=0.416, P<0.05) (Fig. 2) In synovial fluid and serum, collected on the same day, we measured a significantly smaller ratio of PyruDpyr compared with that of synovial tissue (P<0.05) (Fig. 1) , but there was no significant difference in the PyruDpyr ratio in synovial fluid and serum between the diagnosis groups (except for iRA vs OA) and no correlation of PyruDpyr ratio in synovial fluid and serum with ESR and CRP in RA and OA. In synovial tissue of RA patients there was a strong correlation between pyridinoline and deoxypyridinoline levels (r=0.944, P<0.0001), but not in synovial fluid, serum and urine.
The PyruDpyr ratio in urine was found to be elevated in aRA patients compared with iRA (P<0.005) and OA (P<0.005) (Fig. 1) . In RA, but not in OA, the urinary PyruDpyr ratio was found to be correlated with that of synovial tissue (r=0.734, P<0.005) (Fig. 3) . Compared with the serum PyruDpyr ratios, found in equal ranges in all diagnosis groups and independent of those of synovial tissue, the urinary ratios increased according to an averaged factor of 1.96 in RA and 2.14 in OA, indicating a renal concentration of pyridinoline.
Discussion
The levels of hydroxypyridinium collagen crosslinks in urine were found to be in agreement with the data of previous studies. Urinary excreted crosslinks in RA patients were repeatedly reported to be in ranges of 50-90 (pyridinoline) and 10-25 (deoxypyridinoline) nmolumol creatinine, and were related to disease activity w12, 16, 17x. In OA patients, urinary crosslinks were also similar to those reported previously w9, 10x. The quantitative detection of pyridinoline and deoxypyridinoline by HPLC in synovial fluid and serum has been reported. Mueller et al. w7x detected pyridinoline and deoxypyridinoline in synovial fluid and serum of RA patients and found similar amounts to those described in this study. We found an increased amount of total pyridinoline crosslinks per mol of collagen in the synovial tissue of RA patients, significantly correlated with the activity of disease. Because of the complete hydrolysis of synovial tissue, the HPLC measurement estimates both the pyridinium compounds crosslinking the synovial tissue collagen and related collagen crosslinks which have migrated from the collagen of associated joint tissues such as cartilage and bone into the synovial tissue.
Assuming that pyridinoline and deoxypyridinoline from cartilage and bone penetrate in insignificant amounts and similar rates into synovial tissue, the elevation of total pyridinoline and PyruDpyr ratio, respectively, in synovial tissue and urine indicates an increased crosslinking density of mature collagen in synovial tissue of aRA. Therefore the increased urinary crosslink excretion found to be correlated with higher disease activity in RA may possibly be due to both the increased activity of fibroblast-derived collagenases and metalloproteinases w1x and an increased crosslinking activity that provides more 'substrate' for degradation.
The correlation of increased total PyruDpyr in synovial tissue and its urinary excretion indicates that the crosslink measurement in the synovial tissue of the knee joint seems to point to synovial metabolism of pyridinium crosslinks under conditions of inflammation. Polyarticular involvement and the extent to which other, partially inflammation-independent collagen-destructing processes (such as post-menopausal osteoporosis or steroid therapy) contribute to urinary pyridinium excretion do not influence the specifity and sensitivity and the significance of differences of urinary crosslink measurement between the diagnosis groups. Urinary pyridinoline excretion may be confirmed as a marker of inflammation-mediated synovial tissue collagen destruction in RA and OA patients w12, 18x.
Moreover, for the first time we describe an increased pyridinoline crosslinking of synovial tissue mature collagen, correlating with activity parameters of RA. Results obtained demonstrate clearly that a higher grade of inflammation in RA provides not only an increased breakdown of synovial tissue collagen, but also an increased crosslinking in the inflamed tissue. Oxidative deamination of lysine and hydroxylysine is required for collagen crosslinking specifically catalysed by the copper-dependent lysyl oxidase. Intermediate aldehydes are formed and condense spontaneously to crosslinked collagen forming a mature extracellular matrix w19, 20x. An inflammation-dependent increased lysyl oxidase expression in fibroblasts has been described in different types of fibrosis w21x, in wound healing w22x and in the skin of scleroderma patients w23x. Conforming to these immunohistochemical studies, lysyl oxidase expression of cultured osteoblasts and fibroblasts could be regulated with inflammation mediators including transforming FIG. 1. The PyruDpyr ratio estimated in synovial tissue, synovial fluid, serum and urine (for data and statistics see Table 2 ). j active RA (CRP028 mgul); j inactive RA (CRP<28 mgul); I osteoarthritis.
Collagen crosslinking density of RA synovium 317 Collagen crosslinking density of RA synovium 317 growth factor-b1, interleukin (IL)-1b and prostaglandin E2 w24-26x. Furthermore, other cytokines w27x, oxidative stress w28x or direct T-cell contact w29x regulate the fibroblastic collagen synthesis in various tissues. However, there are no investigations on crosslinking density in collagen released from synovial fibroblasts with respect to these factors. Moreover, in collagen there is an underlying increase in crosslinking with age, which is further enhanced in active inflammation of RA. But these modifications seem to be associated with the formation of advanced glycation end products, such as the pentosidine crosslink w30, 31x, and are not relevant for the measurement of increased pyridinium crosslinks. Chen et al. w32x have described markedly increased pentosidine crosslinking with ageing in human yellow ligament hydrolysates, whereas the pyridinoline and deoxypyridinoline crosslinks were found to be unchanged with age. In accordance with that, we found no correlation of synovial tissue pyridinoline and deoxypyridinoline with the age of patients and duration of disease (data not shown).
The consequences of the formation of highly crosslinked collagen in active RA are still unknown. Possibly the inflammed tissue shows an increased antigenic activity triggering further autoimmune processes in active RA. Recently Kim et al. w33x reported increased levels of anti-type II collagen IgG antibodies in RA compared with OA, correlating positively with acutephase reactants and the pro-inflammatory cytokines tumour necrosis factor-a and IL-6 in RA.
Different results have been published concerning the excretion of deoxypyridinoline in RA and OA patients. Seibel et al. w18x found increased excretion of deoxypyridinoline in RA patients and concluded this to be a result of increased bone degradation. Similarly, Kollerup et al. w17x found a 40% increase of urinary deoxypyridinoline in RA patients and found a significant correlation with ESR, CRP and number of swollen joints. In contrast to this, unchanged deoxypyridinoline excretion has been reported in RA patients compared with normal controls in two other studies w6, 34x. Discrepancies have been discussed with respect to different stages of disease activity, menopausal status, age and sex between cases and controls w17x. We also did not find any significant differences in urinary deoxypyridinoline excretion between RA and OA patients and in comparison with normal controls, as measured with the same HPLC method and published from our group w12x. Furthermore, no difference in total deoxypyridinoline levels could be found in hydrolysed synovial tissue from RA and OA patients. This may be due to a very slow activity of the bone destruction process w17x anduor a slow penetration of deoxypyridinoline from bone into synovial tissue. Thus, increased PyruDpyr ratios most probably reflect elevated collagen II degradation of non-osseous joint tissues.
In conclusion, observations from this study demonstrate urinary excretion of pyridinium crosslinks, expressed as the PyruDpyr ratio, to be a marker of collagen degradation of joint tissues in RA patients correlating with current disease activity. Furthermore, an increase of synovial tissue total collagen crosslinking that correlates with the ongoing level of disease activity implicates an influence of RA inflammation on the structure and properties of the extracellular matrix of joint tissues.
